The late stage chronic kidney disease drugs market was valued at US$ 4,680.0 million in 2019 and is projected to reach US$ 11,096.9 million by 2027; it is expected to grow at a CAGR of 11.6% during 2020–2027.
The growth of the late stage chronic kidney disease drugs market is mainly attributed to the factors such as high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs. However, delay in the diagnosis of chronic kidney disease is expected to hamper the growth of the market up to certain extent during the forecast period.
Late-stage renal disease, also called end-stage kidney disease, occurs when chronic kidney disease (the gradual loss of kidney function) reaches an advanced state.In end-stage renal disease, kidneys are no longer able to work as they should to meet the body’s needs.
At this advanced stage, the kidney loses its ability to function effectively, and eventually dialysis or a kidney transplant is needed to save the life.
At present, there is no cure for chronic kidney disease, and treatment involves the managing of the disease.Blood pressure medications, such as angiotensin receptor blockers or angiotensin-converting enzyme inhibitors, are frequently prescribed to control hypertension, and expectantly, to slowdown the progression of chronic kidney disease.
Therefore, the manufacturers in the market are focusing on adopting strategies such as product launches and approvals, R&D investments, government funding, and partnerships to develop new drugs and provide easy access for the patients worldwide. Some of the manufactures are mentioned below:
• DiaMedica Drugs
On February 14, 2019 DiaMedica Drugs Inc, a clinical-stage biotechnology company, announced that it has initiated dosing patients with chronic kidney disease in a Phase Ib clinical study evaluating DM199. The course is conducted in the U.S., is a multi-center, open-label clinical trial to assess the tolerability, safety, and pharmacokinetics of three dose levels of DM199 in 32 patients with moderate and severe CKD. This study will help determine the dose levels required to restore normal KLK1 protein levels in patients with CKD and provide extra insights about the specific CKD patient populations that may benefit most from DM199 treatment and guide the upcoming design Phase II studies. • Cara Drugs, Inc.
Cara Drugs, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to improve pruritus and pain by selectively targeting peripheral kappa opioid receptors, on July 2017 announced that it had dosed the first patient in its Phase 1 pharmacokinetic and safety trial of Oral CR845 tablets in patients with stage III-V chronic kidney disease (CKD) who are not on dialysis. • Akebia Drugs
Akebia Drugs, Inc., a biopharmaceutical company engaged in the development of the with the purpose to better the lives of people impacted by kidney disease, on June 2020 announced the first regulatory approval of vadadustat, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of anemia due to chronic kidney disease (CKD). Moreover, Mitsubishi Tanabe Pharma Corporation, Akebia’s collaboration partner in Japan for vadadustat, has received manufacturing and marketing approval of vadadustat as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients by the Ministry of Health, Labour, and Welfare in Japan. Mitsubishi Tanabe Pharma Corporation will market Vadadustat in Japan under the trade name VAFSEO.
Based on product type, the market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the highest share of the late stage chronic kidney disease drugs market in 2019 and is estimated to register the highest CAGR of 12.1% in the market during the forecast period.
Based on indication, the global late stage chronic kidney disease drugs market is segmented into late stage chronic kidney disease induced hyperparathyroidism, late stage chronic kidney disease induced hyperphosphatemia, and late stage chronic kidney disease induced hyperkalemia. The late stage chronic kidney disease induced hyperparathyroidism segment held the largest share of the market in 2019 and is estimated to register the highest CAGR of 12.1% in the market during the forecast period.
The World Health Organization (WHO), Food and Drug Administration (FDA), European Federation of Pharmaceutical Industry Associations, Pharmaceutical Research, National Kidney Foundation, and Organization for Economic Cooperation and Development are among the major primary and secondary sources referred for preparing this report.
Our reports have been used by over 10K customers, including:
The major factors attributing to the growth of the biosurgery market are increasing geriatric population, rising prevalence of chronic diseases and related surgeries, and a strong focus on R&D leading to the launch of new and advanced products. The global increase in the number of geriatrics population and obese people is likely to...
The global autoinjectors market is projected to reach USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9% from 2020 to 2025. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages,...
Taking care: increasing chronic disease management will drive industry revenue growth Abstract Home Care Providers in the US The Home Care Providers industry is among the fastest-growing healthcare industries in the United States. Home care saves patients billions of dollars every year by treating them...
Certain factors that are driving the market growth include rising healthcare expenditure, growing burden of chronic diseases and advances in drug discovery and development. The burden of chronic diseases is increasing worldwide. According to WHO, chronic diseases have always been a massive global challenge, and they account for approximately...
17 pages •
By Euromonitor International
• Jan 2021
Natural increase will be the sole driver of population expansion in the Dominican Republic up to 2040. While ageing will be a key trend, with rapid growth in the elderly and a decline in the younger age groups, the country will remain relatively young as birth rates remain comparatively high. Nevertheless, as population composition alters...
The Nitinol Medical Devices Market is expected to register a CAGR of 9.1% over the forecast period. Growing burden of diseases and increasing adoption of minimally invasive surgeries is expected to propel the global nitinol medical devices market growth. Nitinol known for its super-elasticity, has wide number of applications in the healthcare...
17 pages •
By Euromonitor International
• Oct 2020
A combination of natural increase and positive net migration will drive population growth in Ireland up to 2040. Ageing will continue to be a key demographic trend, though Ireland will remain relatively young in a regional context due to comparatively high birth rates. Longevity will continue to improve, but certain health issues will rise...
Global centesis catheters market is projected to grow at a CAGR of 6.8% The global centesis catheters market is projected to reach USD 633 million by 2025 from USD 426 million in 2019, growing at a CAGR of 6.8% from 2019 to 2025. The key factors driving the growth of this market include the rising target patient population...
Global Surface Disinfectant market is expected to witness a CAGR of 9.95% during the forecast period. Certain factors that are driving the market growth include rising incidence of hospital-acquired infections, growing geriatric population and subsequent growth in the prevalence of chronic diseases, and the increasing number of surgical procedures. Due...
Biochips are being increasingly used in the area of biomedical and biotechnological research. With the advancement of technology in the medical field, there has been a rise in adoption of biochips in proteomics, such as in microarrays. The advantages of protein biochips include low sample consumption and its inclination towards miniaturization....
Chronic Disease Prevalence
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.